Abstract
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Value in HealthArticle info
Publication history
Publication stage
In Press Accepted ManuscriptFootnotes
Précis: The second paper in this series describes the methods used to tackle the vast literature base on this topic and to provide timely solutions.
Author contributions
Concept and design: Akehurst, Murphy, Solà-Morales, Cunningham, Mestre-Ferrandiz, de Pouvourville
Acquisition of data: Murphy, Franklin
Analysis and interpretation of data: Akehurst, Murphy, Solà-Morales, Cunningham, Mestre-Ferrandiz, Franklin, de Pouvourville
Drafting of the manuscript: Akehurst, Murphy, Solà-Morales, Cunningham, Mestre-Ferrandiz, Franklin, de Pouvourville
Critical revision of the paper for important intellectual content: Akehurst, Murphy, Solà-Morales, Cunningham, Mestre-Ferrandiz, Franklin, de Pouvourville
Statistical analysis:
Provision of study materials or patients:
Obtaining funding: Akehurst, Murphy, Solà-Morales, Cunningham, Mestre-Ferrandiz, de Pouvourville
Administrative, technical, or logistic support:
Supervision:
Other:
Conflict of Interest Disclosures
Prof Akehurst and Dr Murphy are employees of Lumanity, which received funding from Novartis AG for the work submitted. Lumanity also received funding from Novartis AG outside the submitted work. Drs Solà-Morales and Cunningham reported receiving institutional fees from Novartis AG for the work submitted, and also reported receiving institutional fees from Novartis AG outside of the work submitted. Dr Mestre-Ferrandiz and Prof de Pouvourville received personal fees from Novartis AG for the work submitted. Dr Franklin received institutional fees from Novartis AG for the work submitted. Prof de Pouvourville has also received personal fees from Novartis AG outside the submitted work. None of the authors declare any patents or copyrights, or any other personal relationships of relevance. No other disclosures were reported.
Description of the article
Real-world evidence is not always readily accepted by agencies responsible for reimbursement and pricing for new pharmaceuticals. This paper describes how the researchers tackled the vast literature base and used key stakeholder engagement and case studies to produce recommendations. Using a pragmatic and iterative approach allowed us to develop practical tools in a timely manner, which can support improvements in this area.
